Their anti-inflammatory effects ... spironolactone, low-dose corticosteroids, isotretinoin, and dapsone. Spironolactone, an androgen receptor blocker, may be used alone (25-200 mg/day) or in ...

Each arm was further randomized to receive spironolactone 25 mg daily or placebo. The current data compare ... Colchicine’s reported effects on these endpoints, including repeat MI, urgent ...

The spironolactone report counted the 7,062 patients randomized to spironolactone 25 mg once daily versus placebo within 72 hours following PCI. Patients logged a median 3 years of follow-up.

The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a suggestion that it did prevent new or worsening heart failure.

Whether routine use of spironolactone is beneficial after myocardial infarction is uncertain. In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients with ...

Patients with acute MI were randomized in 1:1 fashion to receive spironolactone 25 mg daily (n = 3,537) or placebo (n = 3,525) following PCI, preferably with the Boston Scientific SYNERGY ...

In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

A new study that investigates low-dose ketamine (LDK) as an adjunct to morphine for treating acute pain has been published in the October issue of Academic Emergency Medicine (AEM), the peer-reviewed ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Like, what if penetration just isn’t it for you? Enter: “side,” an alternative to the top/bottom/vers trifecta. Coined by psychotherapist Joe Kort, PhD, clinical sexologist and author of ...